Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
INO-5151
- Development stage
- Phase 1
- Lead developer
- Inovio Pharmaceuticals
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
INO-5151 is a therapeutic cancer vaccine composed of a combination of DNA plasmids encoding interleukin-12 (via the INO-9012 formulation), prostate-specific antigen (PSA), and prostate-specific membrane antigen (PSMA) (via the INO-5150 formulation). It is designed to stimulate an anti-tumor immune response by activating cytotoxic T lymphocytes against prostate cancer cells. The drug is administered intramuscularly with electroporation to enhance cellular uptake. Developed primarily for metastatic castration-resistant prostate cancer (mCRPC), it has been evaluated in combination with other immunotherapies such as CDX-301 (FLT3 ligand) and nivolumab in clinical trials. The primary developer is Inovio Pharmaceuticals, often in collaboration with the Parker Institute for Cancer Immunotherapy[1][2][4][6].
- Other names
- INO-5150 + INO-9012INO-5150 plus INO-9012INO5150 plus INO-9012INO 5150 plus INO-9012
02
Targets
IL-12R (Interleukin-12 receptor)
Beyond the preview
Go deeper on INO-5151.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on INO-5151.